Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) shares passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $47.32 and traded as high as $48.28. Prestige Consumer Healthcare shares last traded at $47.9880, with a volume of 531,104 shares trading hands.
Analysts Set New Price Targets
Several research firms have issued reports on PBH. Zacks Research downgraded Prestige Consumer Healthcare from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 29th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 22nd. Finally, Canaccord Genuity Group reduced their price objective on Prestige Consumer Healthcare from $72.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, November 6th. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of "Hold" and a consensus price target of $67.00.
Read Our Latest Report on Prestige Consumer Healthcare
Prestige Consumer Healthcare Price Performance
The company has a debt-to-equity ratio of 1.08, a current ratio of 2.92 and a quick ratio of 1.86. The company's 50-day simple moving average is $47.32 and its 200-day simple moving average is $53.17. The stock has a market capitalization of $2.27 billion, a P/E ratio of 14.81, a price-to-earnings-growth ratio of 1.44 and a beta of 0.30.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $1.13 earnings per share for the quarter, topping analysts' consensus estimates of $1.07 by $0.06. The firm had revenue of $336.31 million for the quarter, compared to the consensus estimate of $329.14 million. Prestige Consumer Healthcare had a return on equity of 11.28% and a net margin of 13.29%. The business's revenue was up 22.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.07 earnings per share. As a group, sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.50 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in PBH. BlackRock Inc. acquired a new stake in Prestige Consumer Healthcare during the 2nd quarter valued at $370,187,000. Dimensional Fund Advisors LP boosted its position in Prestige Consumer Healthcare by 3.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company's stock worth $158,414,000 after purchasing an additional 91,710 shares during the period. Rice Hall James & Associates LLC acquired a new position in shares of Prestige Consumer Healthcare in the second quarter valued at $32,602,000. The Manufacturers Life Insurance Company acquired a new position in shares of Prestige Consumer Healthcare in the second quarter valued at $31,135,000. Finally, Bank of America Corp DE acquired a new position in shares of Prestige Consumer Healthcare in the second quarter valued at $26,277,000. 99.95% of the stock is owned by institutional investors and hedge funds.
Prestige Consumer Healthcare Company Profile
(
Get Free Report)
Prestige Consumer Healthcare, Inc. develops, markets and distributes over-the-counter health and personal-care products. Its portfolio includes brands such as Dramamine for motion sickness, Clear Eyes for eye care, Chloraseptic for sore-throat relief, Compound W for wart removal, and Summer's Eve for feminine care. The company's products serve categories including eye and ear care, cough and cold relief, pain relief, digestive health, and women's health. They are sold through retail channels such as drugstores, supermarkets, mass-market retailers and online sellers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.